Alfa, MD, discusses neratinib and its use as a monotherapy and in combination with immune checkpoint inhibitors and/or mTOR inhibitors in the SUMMIT trial.

A panelist discusses how loncastuximab tesirine, an antibody-drug conjugate targeting CD19, shows promise in combination with rituximab for R/R FL based on its complementary mechanism of action ...

Experts examine both overall survival outcomes and independent review committee–assessed progression-free survival data from ...

Potential practice-changing therapies in gynecologic cancer include the emergence of carboplatin, paclitaxel, and PD-1 ...

A new drug application seeking the accelerated approval of dordaviprone forrecurrent for H3K27M-mutant diffuse glioma treatment was submitted to the FDA.

Sacituzumab govitecan, currently indicated in triple-negative breast cancer (TNBC), is undergoing evaluation in NSCLC. In ...

Panelists discuss how to approach treatment decisions for a 74-year-old patient with transplant-ineligible newly diagnosed multiple myeloma patient, considering factors such as age, comorbidities, and ...

The FDA indicated paxalisib's overall survival data could support standard approval in glioblastoma, as supported by ...

Aimee Merino, MD, discusses how the identification, evaluation, and management of high-risk disease in early relapsed/refractory multiple myeloma (R/R MM) involves prioritizing specific risk factors, ...

Eunice S. Wang, MD, discusses a retrospective study of 105 patients diagnosed with secondary acute myeloid leukemia.

Thomas W. LeBlanc, MD, MA, discusses how the COMMANDS study, which compared luspatercept to epoetin alfa in erythropoiesis-stimulating agent (ESA)–naive, transfusion-dependent patients with low-risk ...

A panelist discusses how infusion-related reactions to monoclonal antibodies in EGFR-mutated NSCLC can be effectively managed through preventive measures demonstrated in the phase 2 SKIPPirr trial.